This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Patrick C. Walsh, MD; James D. Brooks, MD

JAMA. 1997;277(6):497-498.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of THE JOURNAL, investigators from Sweden present their 15-year results of expectant management of prostate cancer.¹ They conclude that localized prostate cancer has a favorable outlook following watchful waiting and that the number of deaths potentially avoidable by initial radical treatment is limited. These results sound encouraging and suggest that the aggressive approach to early diagnosis and therapy currently used by many physicians in the United States may constitute overtreatment. However, prostate cancer is far from being a benign disease in Sweden. Sweden has the fourth-highest age-adjusted mortality rate from prostate cancer in the world, 21% higher than the United States, which ranks 13th.² This article thus presents a conundrum: if watchful waiting in localized disease results in few deaths, why is the overall mortality from prostate cancer in Sweden high?

See also p 467.

In the 223 cases of localized prostate cancer managed with . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Urology, The Johns Hopkins University School of Medicine and the James Buchanan Brady Urological Institute, The Johns Hopkins University Hospital, and The Johns Hopkins Medical Institutions, Baltimore, Md. (Drs Walsh and Brooks)

Footnotes
Reprints: Patrick C. Walsh, MD, Department of Urology, Marburg 134, The Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287-2101.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?